Investigational Drug Information for rilzabrutinib
✉ Email this page to a colleague
What is the drug development status for rilzabrutinib?
rilzabrutinib is an investigational drug.
There have been 8 clinical trials for rilzabrutinib.
The most recent clinical trial was a Phase 1 trial, which was initiated on January 8th 2019.
The most common disease conditions in clinical trials are Dermatitis, Atopic, Purpura, Thrombocytopenic, Idiopathic, and Dermatitis. The leading clinical trial sponsors are Sanofi, Principia Biopharma, a Sanofi Company, and Principia Biopharma Inc.
There is one US patent protecting this investigational drug and thirty-seven international patents.
Summary for rilzabrutinib
| US Patents | 1 |
| International Patents | 37 |
| US Patent Applications | 5 |
| WIPO Patent Applications | 7 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2019-01-08) |
| Vendors | 32 |
Recent Clinical Trials for rilzabrutinib
| Title | Sponsor | Phase |
|---|---|---|
| Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma | Sanofi | Phase 2 |
| Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to Omalizumab | Sanofi | Phase 2 |
| Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA) | Sanofi | Phase 2 |
Clinical Trial Summary for rilzabrutinib
Top disease conditions for rilzabrutinib
Top clinical trial sponsors for rilzabrutinib
US Patents for rilzabrutinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| rilzabrutinib | ⤷ Try a Trial | Pyrazolopyrimidine compounds as kinase inhibitors | Principia Biopharma Inc. (South San Francisco, CA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for rilzabrutinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| rilzabrutinib | Australia | AU2013312296 | 2032-09-10 | ⤷ Try a Trial |
| rilzabrutinib | Brazil | BR112015003859 | 2032-09-10 | ⤷ Try a Trial |
| rilzabrutinib | Canada | CA2882367 | 2032-09-10 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
